During the past decade, Virginia Clinical Research, Inc. conducted 82 clinical trials. In the 10-year time frame, 82 clinical trials started and 69 clinical trials were completed, i.e. on average, 84.1% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 40 clinical trials were completed. i.e. 160% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Virginia Clinical Research, Inc." #1 sponsor was "Pfizer" with 15 trials, followed by "Eli Lilly and Company" with 12 trials sponsored, "LEO Pharma" with 7 trials sponsored, "DUSA Pharmaceuticals, Inc." with 6 trials sponsored and "Amgen" with 6 trials sponsored. Other sponsors include 103 different institutions and companies that sponsored additional 71 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Virginia Clinical Research, Inc." #1 collaborator was "Dermira, Inc." with 4 trials as a collaborator, "Virginia Clinical Research, Inc." with 3 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "TKL Research, Inc." with 2 trials as a collaborator and "Abbott" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Virginia Clinical Research, Inc." are "Psoriasis" (20 trials), "Atopic Dermatitis" (19 trials), "Acne Vulgaris" (15 trials), "Actinic Keratosis" (11 trials) and "Plaque Psoriasis" (10 trials). Many other conditions were trialed in "Virginia Clinical Research, Inc." in a lesser frequency.

Most popular intervention types in "Virginia Clinical Research, Inc." are "Drug" (133 trials), "Other" (15 trials), "Biological" (13 trials), "Device" (9 trials) and "Procedure" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (46 trials), "Vehicle" (18 trials), "Apremilast" (5 trials), "Lebrikizumab" (5 trials) and "ASN002" (4 trials). Other intervention names were less common.

The vast majority of trials in "Virginia Clinical Research, Inc." are 147 trials for "All" genders, 4 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Virginia Clinical Research, Inc.". undefined are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 121 completed trials in Virginia Clinical Research, Inc., undefined suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in Virginia Clinical Research, Inc., 4 "Phase 1" clinical trials were conducted, 66 "Phase 2" clinical trials and 65 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 2 trials that are defined as “Not Applicable".